Evidence map›Paper›PMID 36251167›Full record

ArticleAdvances in therapy2022

A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma.

Andrew Menzies-Gow, David J Jackson, Mona Al-Ahmad, Eugene R Bleecker, Francisco de Borja G Cosio Piqueras, Stephen Brunton, Giorgio Walter Canonica, Charles K N Chan, John Haughney, Steve Holmes and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. A Patient Charter for Chronic Urticaria.Advances in therapy · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 7 countries.

Andrew Menzies-GowRoyal Brompton and Harefield Hospitals, School of Immunology and Microbial Sciences, King's College, London, UK. a.menzies-gow@rbht.nhs.uk.
David J JacksonGuy's Severe Asthma Centre, School of Immunology and Microbial Sciences, King's College, London, UK.
Mona Al-AhmadMicrobiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait.
Eugene R BleeckerDepartment of Medicine, University of Arizona College of Medicine, Tucson, AZ, USA.
Francisco de Borja G Cosio PiquerasSon Espases University Hospital-IdISBa-Ciberes, Mallorca, Spain.
Stephen BruntonPrimary Care Respiratory Group, Winnsboro, SC, USA.
Giorgio Walter CanonicaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Charles K N ChanFaculty of Medicine, University of Toronto, Toronto, ON, Canada.
John HaughneyGlasgow Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, UK.
Steve HolmesPark Medical Practice, Shepton Mallet, UK.
Janwillem KocksGeneral Practitioners Research Institute, Groningen, The Netherlands.
Tonya WindersAllergy and Asthma Network, Vienna, VA, USA.
Harefield Hospital · GBHospital Universitario Son Espases · ESHumanitas University · ITKing's College London · GBKuwait University · KWQueen Elizabeth University Hospital · GBShepton Mallet Community Hospital · GBUniversity Medical Center Groningen · NLUniversity of Arizona · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma is a heterogenous respiratory disease, usually associated with chronic airway inflammation and hyper-responsiveness, which affects an estimated 339 million people worldwide. Severe asthma affects approximately 5-10% of patients with asthma, approximately 17-34 million people globally, more than half of whom have uncontrolled disease. Severe asthma carries a substantial burden of disease, including unpredictable symptoms and potentially life-threatening flare-ups. Furthermore, severe asthma has a substantial burden on health care systems and economies worldwide. In 2018, a group of experts from the clinical community, patient support groups, and professional organisations joined together to develop the Severe Asthma Patient Charter, which set out six principles to define what patients should expect for the management of their severe asthma and what should constitute a basic standard of care. Since the publication of that original Charter in 2018, several important changes have occurred, including an improved understanding of asthma and effective asthma management; several new therapies have become available; and finally, the COVID-19 pandemic has placed a spotlight on respiratory conditions, the workforces that treat them, and the fundamental importance of health care system resilience. With those developments in mind, we, representatives of the academic, clinical, and patient advocacy group communities, have updated the Charter to Improve Patient Care in Severe Asthma with a focus on six principles: (1) I deserve a timely, comprehensive assessment of my asthma and its severity; (2) I deserve a timely, straightforward referral to an appropriate specialist for my asthma when it is not well controlled; (3) I deserve to understand what makes my asthma worse; (4) I deserve access to treatment and care that reduces the impact of asthma on my daily life; (5) I deserve not to be reliant on systemic corticosteroids; (6) I deserve to be involved in decisions about my treatment and care.

Indexed as

AsthmaCOVID-19HumansPandemicsPatient CareReferral and ConsultationHealth carePatient advocacySevere asthma

Identifiers

PMID36251167
PMCPMC9573814
OpenAlexW4306377497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.